Emergent BioSolutions Secures $24M Contract for Anthrax Vaccine Amid Bioterrorism Threats
Event summary
- Emergent BioSolutions awarded a $24M contract modification by BARDA for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted).
- CYFENDUS® approved by FDA in July 2023 for post-exposure prophylaxis of anthrax in adults 18-65.
- Contract supports U.S. government's anthrax preparedness efforts, following a $21.5M BioThrax® delivery order earlier this year.
The big picture
The $24M contract modification underscores the ongoing need for biodefense preparedness, particularly against anthrax, a persistent biological threat. Emergent's role as a key supplier to the U.S. government highlights its strategic position in the biopharmaceutical sector, where government contracts and public health mandates drive demand. The company's ability to secure such contracts reflects its expertise in manufacturing and supplying critical medical countermeasures, positioning it as a vital player in national security and public health.
What we're watching
- Government Spending
- How sustained U.S. government investment in biodefense will impact Emergent's revenue streams.
- Vaccine Efficacy
- Whether CYFENDUS® can maintain its position as a critical medical countermeasure against anthrax.
- Market Competition
- The pace at which competitors develop alternative anthrax vaccines, potentially disrupting Emergent's market share.